Sugi Predict

Sugi Predict / Targets / MAP2K1

MAP2K1

Dual specificity mitogen-activated protein kinase kinase 1 · Q02750 · MAP2K1 on Sugi Atlas →

113,933 patent compounds predicted against MAP2K1, 76,133 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Selumetinib Selumetinib (SCHEMBL155456) 1.00 20/20
SCHEMBL187560 SCHEMBL187560 1.00 20/20
SCHEMBL188324 SCHEMBL188324 1.00 20/20
SCHEMBL188571 SCHEMBL188571 1.00 20/20
Cobimetinib Cobimetinib (SCHEMBL188704) 1.00 20/20
SCHEMBL188585 SCHEMBL188585 0.82 20/20
SCHEMBL188517 SCHEMBL188517 0.80 20/20
SCHEMBL188233 SCHEMBL188233 0.76 20/20
SCHEMBL188572 SCHEMBL188572 0.72 20/20
SCHEMBL188518 SCHEMBL188518 0.71 20/20
SCHEMBL188543 SCHEMBL188543 0.67 20/20
SCHEMBL188247 SCHEMBL188247 0.65 20/20
SCHEMBL188540 SCHEMBL188540 0.82 19/20
SCHEMBL188456 SCHEMBL188456 0.76 19/20
SCHEMBL188259 SCHEMBL188259 0.73 19/20
SCHEMBL188409 SCHEMBL188409 0.69 19/20
SCHEMBL188387 SCHEMBL188387 0.67 19/20
SCHEMBL188505 SCHEMBL188505 1.00 18/20
Trametinib Trametinib (SCHEMBL170938) 1.00 17/20
Mirdametinib Mirdametinib (SCHEMBL172904) 1.00 17/20

Clinical trials — most relevant to MAP2K1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor PHASE2COMPLETED
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma PHASE2COMPLETED
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Phase I Trial of VS-6766 Alone and in Combination With Everolimus PHASE1COMPLETED
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP2K1 binder may also engage these)

ProteinNameSimilarity
P31938 — 1.000 P31938 →
P29678 — 1.000 P29678 →
Q90891 — 1.000 Q90891 →
Q63980 — 1.000 Q63980 →
Q90321 — 1.000 Q90321 →
Q9XT09 — 0.999 Q9XT09 →
Q91447 — 0.999 Q91447 →
Q01986 — 0.999 Q01986 →
Q05116 — 0.998 Q05116 →
Q63932 — 0.998 Q63932 →
Q1HG70 — 0.998 Q1HG70 →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.998 landscape →
Q99078 — 0.996 Q99078 →
Q07192 — 0.996 Q07192 →
P36506 — 0.995 P36506 →
Q24324 — 0.992 Q24324 →
Q4KSH7 — 0.991 Q4KSH7 →
A9RWC9 — 0.990 A9RWC9 →
MAP2K7 Dual specificity mitogen-activated protein kinase kinase 7 0.990 landscape →
P47809 — 0.989 P47809 →
Q10664 — 0.989 Q10664 →
Q9Y884 — 0.987 Q9Y884 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.986 landscape →
Q7YQL3 — 0.986 Q7YQL3 →
Q5QN75 — 0.986 Q5QN75 →
Q9DGE0 — 0.985 Q9DGE0 →
Q9GRT1 — 0.985 Q9GRT1 →
Q20347 — 0.985 Q20347 →
Q9WVS7 — 0.984 Q9WVS7 →
MAP2K3 Dual specificity mitogen-activated protein kinase kinase 3 0.984 landscape →